Data updated: Jun 28, 2026
PIROXICAM
Immunology
Approved 1982-04-06
20
Indications
--
Phase 3 Trials
44
Years on Market
Details
- Status
- Prescription
- First Approved
- 1982-04-06
- Routes
- ORAL
- Dosage Forms
- CAPSULE
Companies
UNICHEM SOLIS PHARMS Teva IVAX SUB TEVA PHARMS ZYDUS LIFESCIENCES FLAMINGO PHARMS PHARMOBEDIENT Hikma MICRO LABS LTD WATSON LABS INC EGIS Viatris Sun Pharma BRECKENRIDGE STRIDES PHARMA CYCLE SCS
Active Ingredient: PIROXICAM
Website: ↗
PIROXICAM Approval History
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
209 FDA actions from 1992 to 2026
Mar 2026 SUPPL
Label · Labeling
Sep 2025 SUPPL
Label · Labeling
Jul 2024 SUPPL
Label · Labeling
Feb 2024 SUPPL
Label
Oct 2023 SUPPL
Label
Feb 2023 SUPPL
Label
Feb 2023 SUPPL
Label
Aug 2022 SUPPL
Label
Feb 2022 SUPPL
Label
Dec 2019 SUPPL
Label
Oct 2019 SUPPL
Label
Oct 2019 SUPPL
Label
Jul 2018 SUPPL
Mfg
Jul 2018 ORIGINAL
Update
Feb 2018 ORIGINAL
Update
Jan 2018 ORIGINAL
Update
Dec 2017 ORIGINAL
Update
Aug 2017 ORIGINAL
Update
Jun 2017 ORIGINAL
Update
Apr 2017 ORIGINAL
Update
Feb 2016 SUPPL
Label
Sep 2015 SUPPL
Label
Jun 2015 SUPPL
Label
Oct 2011 SUPPL
Label
Sep 2011 SUPPL
Label
Nov 2010 SUPPL
Label
May 2008 SUPPL
Label
Jan 2008 SUPPL
Label
Jul 2006 SUPPL
Label
Apr 2006 SUPPL
Label
Mar 2006 SUPPL
Label
Mar 2006 SUPPL
Label
Jan 2004 SUPPL
Label
Apr 2002 SUPPL
Mfg
Mar 2002 SUPPL
Mfg
Jun 2001 SUPPL
Mfg
Apr 2001 SUPPL
Mfg
Oct 2000 SUPPL
Label
Sep 2000 SUPPL
Mfg
May 2000 SUPPL
Mfg
Mar 2000 SUPPL
Mfg
Jan 2000 SUPPL
Mfg
Dec 1999 SUPPL
Mfg
Apr 1999 SUPPL
Mfg
Mar 1999 SUPPL
Mfg
Feb 1999 SUPPL
Mfg
Sep 1998 SUPPL
Mfg
Jul 1998 SUPPL
Mfg
Mar 1998 SUPPL
Mfg
Feb 1998 SUPPL
Mfg
Jan 1998 SUPPL
Mfg
Dec 1997 SUPPL
Mfg
Oct 1997 SUPPL
Mfg
Aug 1997 SUPPL
Mfg
Jul 1997 ORIGINAL
Update
Jun 1997 SUPPL
Mfg
Feb 1997 SUPPL
Mfg
Sep 1996 SUPPL
Mfg
Jul 1996 SUPPL
Mfg
Jun 1996 ORIGINAL
Update
May 1996 SUPPL
Mfg
May 1996 ORIGINAL
Update
Oct 1995 SUPPL
Mfg
Sep 1995 ORIGINAL
Update
Jul 1994 SUPPL
Mfg
Mar 1994 SUPPL
Mfg
Jan 1994 ORIGINAL
Update
Jan 1994 SUPPL
Mfg
Nov 1993 SUPPL
Label
Oct 1993 SUPPL
Mfg
Aug 1993 SUPPL
Label
Jun 1993 ORIGINAL
Update
Mar 1993 SUPPL
Mfg
Mar 1993 ORIGINAL
Update
Dec 1992 ORIGINAL
Update
Sep 1992 ORIGINAL
Update
Aug 1992 ORIGINAL
Update
Jul 1992 ORIGINAL
Update
May 1992 ORIGINAL
Update
What PIROXICAM Treats
20 FDA approvalsOriginally approved for its first indication in 1992 . Covers 20 distinct patient populations.
- Other (20)
Other
(20 approvals)- • Approved indication (May 1992)
- • Approved indication (Jul 1992)
- • Approved indication (Aug 1992)
- • Approved indication (Sep 1992)
- • Approved indication (Dec 1992)
- • Approved indication (Mar 1993)
- • Approved indication (Jun 1993)
- • Approved indication (Jan 1994)
- • Approved indication (Sep 1995)
- • Approved indication (May 1996)
- • Approved indication (Jun 1996)
- • Approved indication (Jul 1997)
- • Approved indication (Sep 2016)Letter
- • Approved indication (Apr 2017)
- • Approved indication (Jun 2017)
- • Approved indication (Aug 2017)
- • Approved indication (Dec 2017)
- • Approved indication (Jan 2018)
- • Approved indication (Feb 2018)
- • Approved indication (Jul 2018)
📋
Clinical Trial Registry
8 trials| Trial | Sponsor ID | Phase | Status | Title |
|---|---|---|---|---|
| NCT06727734 | UW 24-054 | Ph 3 | recruiting | Levonorgestrel-piroxicam Versus Ulipristal Acetate for Emergency Contraception |
| NCT06404177 PiDex | Dexketoprofene-Piroxicam | Ph 3 | recruiting | Enantyum® IV Versus Piroxen® IM in Emergency Pain Management |
| NCT02304783 ONSAIP-RC | Oral NSAI in RC | Ph 3 | completed | Oral NSAI Versus Paracetamol or Placebo as a Second Line Treatment for Renal Colics |
| NCT05722782 NAP-RC | NAP in RC | Ph 2 | recruiting | Oral NSAI Versus Acetaminophen or Placebo as a Discharge Treatment of Non Complicated Renal Colics |
| NCT05488925 | BDC/ERB/2021/016 | Ph 4 | completed | Comparison of Preoperative Analgesics on the Efficacy of Inferior Alveolar Nerve Block. |
| NCT02450487 results posted | 20657913.7.0000.5417 CAAE | Ph 4 | completed | Influence of Genotype of CYP2C9 on Clinical Efficacy and Pharmacokinetics of Piroxicam After Lower Third Molar Surgery |
| NCT02253446 | MDhayri2014 | Ph 4 | completed | A Comparison of Analgesic İmpacts of Piroxicam and Diclofenac Sodium in the Treatment of Primary Dysmenorrhea |
| NCT00670475 | 1/86010 | Ph 2 | completed | Comparative Study of Olive Oil With Piroxicam Gel in Osteoarthritis of the Knee |
🔬
Pro Active Pipeline
Ongoing clinical trials by development phase
Loading...
⭐
Pro Key Completed Trials
Completed studies with published results, ranked by significance
Loading...
📊
Trial Timeline
Full development history with FDA approval milestones
|
Loading...
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
PIROXICAM FDA Label Details
Looking for the branded version?
FELDENE
Full clinical data, patents, trials, and competitive landscape for piroxicam.
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.